IL6 and COVID-19: Similarly, in an early report on 26 critically ill COVID-19 patients with shock, severe ARDS requiring VV ECMO, renal failure, and severe hyperinflammation (average IL-6: 1068 ± 1277 pg/mL), the early initiation of CytoSorb hemoadsorption was associated with a significant reduction of inflammatory mediators, marked improvement in lung function, hemodynamic stabilization, and 62.5% survival [12].